FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...
(December 27, 2023) Natera Inc. succeeded in obtaining a preliminary injunction against NeoGenomics Laboratories, Inc.’s medical assay test. Natera’s ongoing federal lawsuit alleges that NeoGenomics’ ...
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 11.1% year on year to $186.7 million. The company ...
-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...
NEW YORK, May 26, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, ...
NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...
Bradley T. Adler of Freeman, Mathis & Gary has entered an appearance for NeoGenomics Laboratories Inc. in a lawsuit over alleged sexual harassment and retaliation. The case was filed Feb. 3 in Georgia ...
NeoGenomics has moved to acquire clinical oncology laboratory Genoptix for $125 million in cash plus 1 million shares of stock currently worth over $14 million. The two companies billed the deal as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results